264 related articles for article (PubMed ID: 16928764)
1. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.
Baxter JD; Schapiro JM; Boucher CA; Kohlbrenner VM; Hall DB; Scherer JR; Mayers DL
J Virol; 2006 Nov; 80(21):10794-801. PubMed ID: 16928764
[TBL] [Abstract][Full Text] [Related]
2. Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score.
Schapiro JM; Scherer J; Boucher CA; Baxter JD; Tilke C; Perno CF; Maggiolo F; Santoro MM; Hall DB
Antivir Ther; 2010; 15(7):1011-9. PubMed ID: 21041916
[TBL] [Abstract][Full Text] [Related]
3. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2007 Jan; 21(2):179-85. PubMed ID: 17197808
[TBL] [Abstract][Full Text] [Related]
4. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors.
Talbot A; Grant P; Taylor J; Baril JG; Liu TF; Charest H; Brenner B; Roger M; Shafer R; Cantin R; Zolopa A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2473-9. PubMed ID: 20368406
[TBL] [Abstract][Full Text] [Related]
5. Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.
Marcelin AG; Masquelier B; Descamps D; Izopet J; Charpentier C; Alloui C; Bouvier-Alias M; Signori-Schmuck A; Montes B; Chaix ML; Amiel C; Santos GD; Ruffault A; Barin F; Peytavin G; Lavignon M; Flandre P; Calvez V
Antimicrob Agents Chemother; 2008 Sep; 52(9):3237-43. PubMed ID: 18625773
[TBL] [Abstract][Full Text] [Related]
6. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
[TBL] [Abstract][Full Text] [Related]
7. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
Muzammil S; Armstrong AA; Kang LW; Jakalian A; Bonneau PR; Schmelmer V; Amzel LM; Freire E
J Virol; 2007 May; 81(10):5144-54. PubMed ID: 17360759
[TBL] [Abstract][Full Text] [Related]
8. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.
Doyon L; Tremblay S; Bourgon L; Wardrop E; Cordingley MG
Antiviral Res; 2005 Oct; 68(1):27-35. PubMed ID: 16122817
[TBL] [Abstract][Full Text] [Related]
9. Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.
Bethell R; Scherer J; Witvrouw M; Paquet A; Coakley E; Hall D
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1019-24. PubMed ID: 22098079
[TBL] [Abstract][Full Text] [Related]
10. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
[TBL] [Abstract][Full Text] [Related]
11. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
[TBL] [Abstract][Full Text] [Related]
13. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
de Mendoza C; Morelló J; Garcia-Gascó P; Rodríguez-Novoa S; Soriano V
Expert Opin Pharmacother; 2007 Apr; 8(6):839-50. PubMed ID: 17425479
[TBL] [Abstract][Full Text] [Related]
14. Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy.
Ross L; Liao Q; Gao H; Pham S; Tolson J; Hertogs K; Larder B; Saag MS
AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1379-85. PubMed ID: 11679150
[TBL] [Abstract][Full Text] [Related]
15. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.
de Requena DG; Bonora S; Calcagno A; D'Avolio A; Siccardi M; Fontana S; Milia MG; Sciandra M; Garazzino S; Di Garbo A; Baietto L; Trentini L; Di Perri G
Antimicrob Agents Chemother; 2008 Mar; 52(3):1066-71. PubMed ID: 18160524
[TBL] [Abstract][Full Text] [Related]
16. Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.
Mata-Munguía C; Escoto-Delgadillo M; Torres-Mendoza B; Flores-Soto M; Vázquez-Torres M; Gálvez-Gastelum F; Viniegra-Osorio A; Castillero-Manzano M; Vázquez-Valls E
BMC Bioinformatics; 2014 Mar; 15():72. PubMed ID: 24629078
[TBL] [Abstract][Full Text] [Related]
17. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
18. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
[TBL] [Abstract][Full Text] [Related]
19. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
[TBL] [Abstract][Full Text] [Related]
20. Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.
Saracino A; Monno L; Tartaglia A; Tinelli C; Seminari E; Maggiolo F; Bonora S; Rusconi S; Micheli V; Lo Caputo S; Lazzaroni L; Ferrara S; Ladisa N; Nasta P; Parruti G; Bellagamba R; Forbici F; Angarano G
Curr HIV Res; 2009 Jul; 7(4):425-33. PubMed ID: 19601778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
